<DOC>
	<DOCNO>NCT01978730</DOCNO>
	<brief_summary>As traditional Chinese medicine compound , SaiLuoTong capsule proven beneficial effect learn memory ability animal model vascular dementia ( VaD ) . The study hypothesis SaiLuoTong capsule effective treatment patient VaD well tolerate . The purpose study determine efficacy safety SaiLuoTong capsule patient mild moderate VaD . The outcome measure include general cognitive function , executive function , daily living skill , mental behavior change symptoms VaD patient .</brief_summary>
	<brief_title>The Clinical Trial Chinese Herbal Medicine SaiLuoTong Capsule</brief_title>
	<detailed_description>Vascular dementia ( VaD ) clinical syndrome acquire intellectual functional impairment result cerebrovascular disease . SaiLuoTong capsule traditional Chinese medicine compound ; compose ginseng extract ( main composition : ginseng total saponin ) , ginkgo biloba extract ( main composition : YinXingTong ester ) safflower extract ( main composition : west safflower total glycoside ) . The function SaiLuoTong capsule Yiqi Huoxue Huayu Tongluo Chinese traditional medicine theory . Pharmacodynamics study show SaiLuoTong capsule significantly improve neurological symptom cause focal cerebral ischemia animal , learn memory ability animal model VaD . Based previous evidence , conduct study assess efficacy safety SaiLuoTong capsule patient mild moderate VaD . This study phase 2 clinical trial SaiLuoTong capsule treatment vascular dementia . The initial study 26-week , multicentre , randomize , double -blind , placebo-controlled study . Patients complete initial 26-week trial eligible continue 26-week open-label extension study . The primary secondary objective study follow : Primary Objectives : 1 . To assess efficacy SaiLuoTong capsule cognitive global functioning patient mild-to-moderate VaD ; 2 . To assess safety tolerability SaiLuoTong capsule patient mild-to-moderate VaD . Secondary Objectives : 1 . To assess efficacy SaiLuoTong capsule improve ability activity daily live , executive function , neuropsychiatric symptom patient mild-to-moderate VaD ; 2 . To assess efficacy different dosage regimen SaiLuoTong patient mild-to-moderate VaD ; 3 . To assess efficacy SaiLuoTong treatment different duration patient mild-to-moderate VaD ; 4 . To assess efficacy SaiLuoTong capsule different etiological subtypes VaD , include large-vessel VaD , small-vessel VaD , VaD mix large-vessel small-vessel origin ; 5 . To assess efficacy SaiLuoTong capsule mild VaD patient moderate VaD patient separately ; 6 . To assess effect apolipoprotein E ( ApoE ) ε4 allele trial outcome . The study ass change cognitive function , daily living skill , executive function , behavioral psychological symptom . The primary measure effectiveness include change baseline vascular dementia assessment scale cognitive subscale ( V-ADAS-cog ) Alzheimer 's disease cooperative study-clinical global impression change ( ADCS-CGIC ) . Secondary measure effectiveness include change baseline Alzheimer 's disease cooperative study-activities daily live inventory ( ADCS-ADL ) , mini-mental state examination ( MMSE ) , clinical dementia rating scale ( CDR ) , sum box CDR ( CDR-sb ) , clock draw task ( CLOX ) , Chinese version executive interview 25 ( C-EXIT25 ) neuropsychiatric inventory ( NPI ) . Safety measure include physical examination , vital sign , electrocardiography , laboratory test , adverse event record .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<criteria>40 year old , gender limit ; Education≥primaryschool ; Dementia diagnose accord Diagnostic Statistical Manual Mental Disorders4th Edition ( DSMIV ) criterion ; Probable VaD diagnose National Institute Neurological Disorders StrokeAssociation Internationale pour la Recherche et l'Enseignement en Neurosciences ( NINDSAIREN ) criterion ; Modified Hachinski ischemic scale ( MHIS ) total score≥4 ; Evidence ischemic cerebrovascular disease magnetic resonance imaging ( MRI ) /or CT ( correspond image criterion NINDSAIREN ) Mildtomoderate dementia define MMSE score 10 26 , CDR score 1 2 , inclusive Modified Hachinski ischemic scale ( MHIS ) total score≥4 ; Hamilton depression scale ( HAMD ) total score≤17 ; The patient agree participate study able understand inform consent well sign . In case patient unable , carer 's consent obtain proxy ; There carers accompany patient least 4 day week accompany patient participate visit . Dementia cause brain disease except VaD ( e.g . Alzheimer 's disease , Lewy body dementia , frontotemporal dementia , Parkinson 's disease , demyelinate disease central nervous system , tumour , hydrocephalus , head injury , central nervous system infection include syphilis , acquire immune deficiency syndrome , etc . ) ; The patient complete examination severe brain nerve function loss , convenient hand hemiplegia , sort aphasia audiovisual obstacle , etc ; The presence abnormal laboratory parameter : Hemoglobin ( Hb ) platelet ( Plt ) less low limit ; activate partial thromboplastin time ( APTT ) beyond normal value 10 second , prothrombin time ( PT ) beyond normal value 3 second ; creatinine ( Cr ) 1.5 time upper limit value ; alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphate ( ALP ) , γglutamyl transferase ( γGT ) 2 time upper limit normal , total bilirubin ( TBiL ) 1.5 time upper limit normal ; Nutrition metabolic diseases endocrine system lesion thyroid disease , parathyroid disease , deficiency vitamin element ; Severe circulatory , respiratory , urinary , digestive , hematopoietic system disease ( unstable angina , incontrollable asthma , active bleeding , etc . ) cancer ; Severe mental illness ( depression , schizophrenia ) epilepsy ; Gastrointestinal disorder affect drug absorption , distribution , metabolism ; Alcohol drug abuse ; Patients use stop follow drug include Chinese herba preparation contain ginseng , ginkgo leaf component saffron ; medication may affect cognitive functioning , donepezil , rivastigmine , huperzine A , memantine , nimodipine ; etc . ; Known allergic composition SaiLuoTong ; Pregnancy breastfeed woman ; New stroke within 3 month baseline Had participate clinical trial study 3 month prior study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>vascular dementia</keyword>
	<keyword>cognition</keyword>
	<keyword>stroke</keyword>
</DOC>